SH

Shivalik Rasayan LtdNSE SHIVALIK Stock Report

Last reporting period 31 Mar, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.166

Micro

Exchange

XNSE - National Stock Exchange Of India

SHIVALIK.NS Stock Analysis

SH

Avoid

Based on Eyestock quantitative analysis, SHIVALIK.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

11/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-28.8 %

Greatly overvalued

Market cap $B

0.166

Dividend yield

0.07 %

Shares outstanding

15.56 B

Shivalik Rasayan Ltd. engages in the manufacture of pharmaceutical and agrochemical products. The company is headquartered in New Delhi, Delhi and currently employs 256 full-time employees. The company went IPO on 2015-05-22. The firm is the producer of Dimethoate Technical and the Malathion Technical in India. The company also manufactures organophosphorus-based insecticides and chemicals. Its business units include API, Formulation, Research and Development, Agrochemical, Specialty Chemicals and Intellectual Property. The company offers solutions from product selection to development till commercialization for a range of oncology and non-oncology products. Its oncology products include Azacitidine, Busulfan, Bortezomib, and various others. Its non-oncology products include Fingolimod, Pirfenidone, Ambroxol HCL, and others. Its Dimethoate Technical is used in preparation of formulations used in the control of a range of insect and mites. Its Malathion Technical is a non-systemic, wide spectrum organophosphorus (OP) based contact insecticide used for a variety of food/feed crops.

View Section: Eyestock Rating